Imlifidase therapy: exploring its clinical uses.
Lionel RostaingJohan NoblePaolo MalvezziThomas JouvePublished in: Expert opinion on pharmacotherapy (2022)
The major hurdle now is how to prevent/avoid DSA rebound within days 5-15 post-transplantation. Thus, imlifidase represents a major breakthrough for highly HLA-sensitized kidney transplant candidates, particularly those that have calculated panel-reactive alloantibodies of ≥90%.
Keyphrases